Stock Mover of The Day: Ariad Pharmaceuticals, Inc. Rises A lot Today, Is Now One of The Best Performer

Stock Mover of The Day: Ariad Pharmaceuticals, Inc. Rises A lot Today, Is Now One of The Best Performer

The stock of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is a huge mover today! About 4.59 million shares traded hands. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has risen 88.97% since April 26, 2016 and is uptrending. It has outperformed by 83.71% the S&P500.
The move comes after 6 months positive chart setup for the $2.61B company. It was reported on Nov, 29 by Barchart.com. We have $15.01 PT which if reached, will make NASDAQ:ARIA worth $208.80M more.

Analysts await Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) to report earnings on February, 28. They expect $-0.17 EPS, up 46.88% or $0.15 from last year’s $-0.32 per share. After $-0.14 actual EPS reported by Ariad Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 21.43% negative EPS growth.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Ratings Coverage

Out of 7 analysts covering Ariad Pharmaceuticals (NASDAQ:ARIA), 3 rate it a “Buy”, 2 “Sell”, while 2 “Hold”. This means 43% are positive. Ariad Pharmaceuticals has been the topic of 12 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The company was maintained on Friday, August 7 by JP Morgan. The company was downgraded on Monday, October 24 by JP Morgan. The firm earned “Mkt Perform” rating on Tuesday, October 25 by JMP Securities. The stock of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has “Buy” rating given on Wednesday, October 5 by Suntrust Robinson. The stock of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has “Underweight” rating given on Wednesday, May 11 by Barclays Capital. Leerink Swann initiated Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) on Monday, September 26 with “Outperform” rating. The stock has “Hold” rating given by Deutsche Bank on Thursday, November 3. SunTrust initiated Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) rating on Wednesday, October 5. SunTrust has “Buy” rating and $22 price target. The firm earned “Underweight” rating on Tuesday, January 19 by Barclays Capital. Barclays Capital maintained it with “Underweight” rating and $9 target price in Friday, July 29 report.

According to Zacks Investment Research, “Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology. The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology. The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.”

Insitutional Activity: The institutional sentiment decreased to 1.24 in Q2 2016. Its down 0.16, from 1.4 in 2016Q1. The ratio dropped, as 19 funds sold all Ariad Pharmaceuticals, Inc. shares owned while 44 reduced positions. 30 funds bought stakes while 58 increased positions. They now own 131.89 million shares or 0.58% less from 132.66 million shares in 2016Q1.
Franklin Street Advisors Nc has invested 0.06% of its portfolio in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA). Blackrock Grp Limited holds 0% of its portfolio in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) for 163,527 shares. Fmr Lc last reported 0.01% of its portfolio in the stock. Moreover, Voya Inv Limited has 0% invested in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) for 74,396 shares. Nuveen Asset Ltd Llc last reported 0% of its portfolio in the stock. Seven Eight Capital Ltd Liability Corporation holds 0.04% of its portfolio in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) for 15,800 shares. Cubist Systematic Strategies Lc owns 8,534 shares or 0% of their US portfolio. Raymond James And Associates last reported 0% of its portfolio in the stock. Moreover, Deutsche Bankshares Ag has 0.01% invested in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) for 965,954 shares. Kcg Holding Inc last reported 0.02% of its portfolio in the stock. Quantitative Invest Management Ltd Limited Liability Company has 0.03% invested in the company for 85,200 shares. 1492 Capital Ltd Liability Company, a Wisconsin-based fund reported 202,500 shares. Smith Asset Management Group Ltd Partnership holds 0.01% of its portfolio in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) for 36,250 shares. Ameritas Inv Prtn Inc last reported 0.01% of its portfolio in the stock. Swiss National Bank & Trust owns 282,800 shares or 0% of their US portfolio.

Insider Transactions: Since June 10, 2016, the stock had 0 buys, and 10 insider sales for $3.87 million net activity. On Friday, July 1 CLACKSON TIMOTHY P sold $459,634 worth of the stock or 61,422 shares. $896,135 worth of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) was sold by Radaelli Massimo on Friday, June 10. LAVIDAS ATHANESE had sold 76,250 shares worth $626,039.

More news for Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) were recently published by: Fool.com, which released: “3 Things You Really Need to Know About Ariad Pharmaceuticals, Inc. Q3 Results” on November 07, 2016. Schaeffersresearch.com‘s article titled: “Buzz Stocks: Ariad Pharmaceuticals, Inc., Tiffany & Co., and TiVo Corp” and published on November 29, 2016 is yet another important article.

ARIA Company Profile

ARIAD Pharmaceuticals, Inc. (ARIAD), incorporated on April 12, 1991, is an oncology company. The Firm is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment